CME

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Glaucoma 2017: Controlling IOP and Promoting Adherence through Novel Therapeutics

Glaucoma 2017: Controlling IOP and Promoting Adherence through Novel Therapeutics

This activity is supported by an educational grant from Aerie Pharmaceuticals, Inc.

Overview

Author(s)/Faculty: John R. Samples, MD; Cynthia Mattox, MD, FACS; Steven T. Simmons, MD
Source: Healio - Ophthalmology Education Lab
Type: LectureArticles/Items: 5
Release Date: 2/10/2017Expiration Date: 2/9/2018
Credit Type: CMENumber of Credits: 1
Cost: FreeProvider: Vindico Medical Education

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to stop or slow disease progression. Current glaucoma medications achieve this almost exclusively through reduction of intraocular pressure (IOP). Unfortunately, even with appropriate use of currently available medications, many people with glaucoma will still experience vision loss. Intraocular pressure is the only known modifiable risk factor for patients with glaucoma, so improvements in patient outcomes rely on tight IOP control and patient adherence to therapy. In this educational activity, leading clinicians review established and new therapeutic agents for patients with glaucoma, including the recent clinical evidence for their safety and efficacy. In addition, discussion will include the extent to which patient adherence has a negative impact on the delivery of effective therapy for glaucoma.

CME Information

page 1 of 8